Featured 13F manager
Opaleye Management Inc. James Silverman
Boston, MA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $1.1B
- 58 Positions
- 2026 Q2
- +45.5% QoQ
- Top 5 46.8%
James Silverman files Opaleye Management Inc. as a Form 13F. The latest book is 2026 Q2 at $1.1B, up 45.5% QoQ, led by Liquidia, Eton Pharmaceuticals, and Harrow.
Portfolio
top 5 46.8% · top 10 64.8%
- LQDA - Liquidia 17.7%
- ETON - Eton Pharmaceuticals 9.4%
- HROW - Harrow 9.2%
- IRON - Disc Medicine 5.7%
- URGN - Urogen Pharma 4.8%
- APGE - Apogee Therapeutics 4.7%
- MGTX - Meiragtx 4.3%
- SLGL - Sol-Gel Technologies 3.3%
- RZLT - Rezolute 3.0%
- TGTX - Tg Therapeutics 2.7%
- IMMX - Immix Biopharma 2.2%
- CBIO - Crescent Biopharma 2.1%
- Other 30.9%
AUM over time
Book
| HROW - Harrow Health | 26.60% | Hold | 3,905,000 | $48.18 | $188M | — | — |
| ETON - Eton Pharmaceuticals | 8.79% | Hold | 2,860,000 | $21.73 | $62M | — | — |
| LQDA - Liquidia | 8.41% | Add +5.7% | 2,615,000 | $22.74 | $59M | +140,000 | +$29M |
| RYTM - Rhythm Pharmaceuticals | 6.59% | Reduce −2.8% | 461,700 | $100.99 | $47M | −13,300 | +$17M |
| Immunome | 5.27% | Reduce −9.8% | 3,185,000 | $11.71 | $37M | −344,581 | +$4M |
| SNWV - Sanuwave Health | 5.19% | Hold | 980,000 | $37.48 | $37M | — | — |
| CDXS - Codexis | 4.41% | Add +1.5% | 12,795,000 | $2.44 | $31M | +195,000 | +$476K |
| TGTX - Tg Therapeutics | 2.73% | Hold | 535,000 | $36.12 | $19M | — | — |
| OCUL - Ocular Therapeutix | 2.64% | Hold | 1,595,000 | $11.69 | $19M | — | — |
| CGON - Cg Oncology | 2.33% | Add +54.1% | 410,000 | $40.28 | $17M | +144,000 | +$10M |
| STOK - Stoke Therapeutics | 2.27% | Add +21.3% | 682,017 | $23.50 | $16M | +119,897 | +$10M |
| APGE - Apogee Therapeutics | 2.04% | New | 363,257 | $39.73 | $14M | +363,257 | +$14M |
| ALKS - Alkermes | 1.91% | New | 450,000 | $30.00 | $14M | +450,000 | +$14M |
| IRON - Disc Medicine | 1.81% | Add +3.9% | 193,773 | $66.08 | $13M | +7,355 | +$3M |
| Sarepta Therapeutics | 1.59% | Add +17.0% | 585,000 | $19.27 | $11M | +85,000 | +$3M |
| LRMR - Larimar Therapeutics | 1.49% | Reduce −9.5% | 3,720,867 | $2.84 | $11M | −389,133 | −$1M |
| XOMA - XOMA Del | 1.39% | Hold | 255,087 | $38.54 | $10M | — | — |
| RZLT - Rezolute | 1.20% | Hold | 903,442 | $9.40 | $8M | — | — |
| ARVN - Arvinas | 1.19% | Reduce −41.2% | 987,818 | $8.52 | $8M | −692,182 | −$4M |
| EWTX - Edgewise Therapeutics | 1.15% | Add +2.0% | 500,000 | $16.22 | $8M | +10,000 | +$2M |
| ANNX - Annexon | 1.12% | New | 2,600,000 | $3.05 | $8M | +2,600,000 | +$8M |
| Gossamer Bio | 1.01% | Reduce −23.1% | 2,725,000 | $2.63 | $7M | −820,000 | +$3M |
| PTGX - Protagonist Therapeutics | 0.99% | Hold | 105,000 | $66.43 | $7M | — | — |
| DERM - Journey Medical | 0.98% | Add +922.2% | 971,064 | $7.12 | $7M | +876,064 | +$6M |
| SLGL - Sol Gel Technologies | 0.84% | New | 204,835 | $29.15 | $6M | +204,835 | +$6M |
| PLX - Protalix Biotherapeutics | 0.81% | New | 2,580,556 | $2.22 | $6M | +2,580,556 | +$6M |
| Treace Medical Concepts | 0.67% | New | 702,245 | $6.71 | $5M | +702,245 | +$5M |
| RVMD - Revolution Medicines | 0.66% | Reduce −4.8% | 100,000 | $46.70 | $5M | −5,000 | +$807K |
| MBX - Mbx Biosciences | 0.63% | Add +5.7% | 253,000 | $17.50 | $4M | +13,681 | +$2M |
| TRVI - Trevi Therapeutics | 0.50% | Hold | 390,000 | $9.15 | $4M | — | — |
| ADCT - ADC Therapeutics SA | 0.39% | New | 682,529 | $4.00 | $3M | +682,529 | +$3M |
| ALMS - Alumis | 0.38% | Reduce −14.2% | 665,000 | $3.99 | $3M | −110,000 | +$328K |
| CABA - Cabaletta Bio | 0.27% | New | 808,882 | $2.34 | $2M | +808,882 | +$2M |
| IRD - Opus Genetics | 0.26% | Reduce −9.8% | 1,100,000 | $1.65 | $2M | −120,000 | +$666K |
| Zymeworks | 0.24% | Reduce −52.4% | 100,000 | $17.08 | $2M | −110,000 | −$928K |
| SYRE - Spyre Therapeutics | 0.15% | New | 65,000 | $16.76 | $1M | +65,000 | +$1M |
| RIGL - Rigel Pharmaceuticals | 0.15% | New | 37,787 | $28.33 | $1M | +37,787 | +$1M |
| ACOG - Alpha Cognition | 0.11% | New | 115,142 | $6.51 | $750K | +115,142 | +$750K |
| ZNTL - Zentalis Pharmaceuticals | 0.07% | Reduce −83.5% | 316,550 | $1.51 | $478K | −1,607,750 | −$2M |
| PEPG - Pepgen | 0.05% | Reduce −68.8% | 75,000 | $4.62 | $347K | −165,000 | +$80K |
| IBIO — | 0.04% | Hold | 375,000 | $0.8278 | $310K | — | — |
| ADGM - Adagio Med | 0.03% | Hold | 110,571 | $1.94 | $215K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2025 Q2
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Vigil Neurosciences | 1.59% | Exit | 0 | $7.95 | $8M | −1,000,000 | −$8M |
| Protara Therapeutics | 1.48% | Exit | 0 | $8.62 | $7M | −855,000 | −$7M |
| ANIK - Anika Therapeutics | 1.25% | Exit | 0 | $10.58 | $6M | −588,797 | −$6M |
| DNA - Ginkgo Bioworks · CLASS A | 1.13% | Exit | 0 | $11.25 | $6M | −500,000 | −$6M |
| Essa Pharma | 0.75% | Exit | 0 | $1.70 | $4M | −2,209,998 | −$4M |
| Cargo Therapeutics | 0.55% | Exit | 0 | $4.12 | $3M | −666,503 | −$3M |
| RCEL - Avita Medical | 0.41% | Exit | 0 | $5.29 | $2M | −389,519 | −$2M |
| Elevation Oncology | 0.11% | Exit | 0 | $0.3668 | $529K | −1,442,061 | −$529K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 58 | $1.1B | +45.5% | 13F-HR | 8/14/2026 | 000142050626001803 |
| 2026 Q1 | 54 | $759M | +0.1% | 13F-HR | 5/15/2026 | 000142050626001151 |
| 2025 Q4 | 54 | $758M | — | RESTATEMENT | 4/13/2026 | 000149315226016299 |
| 2025 Q4 | 54 | $758M | +7.2% | 13F-HR | 2/17/2026 | 000149315226007085 |
| 2025 Q3 | 43 | $707M | +41.7% | 13F-HR | 11/14/2025 | 000149315225023429 |
| 2025 Q2 | 41 | $494M | — | RESTATEMENT | 8/15/2025 | 000164117225024301 |
| 2025 Q2 | 41 | $499M | +11.1% | 13F-HR | 8/14/2025 | 000164117225023977 |
| 2025 Q1 | 45 | $449M | −21.4% | 13F-HR | 5/15/2025 | 000164117225010914 |
| 2024 Q4 | 39 | $571M | −4.8% | 13F-HR | 2/14/2025 | 000149315225006852 |
| 2024 Q3 | 44 | $600M | +37.0% | 13F-HR | 11/14/2024 | 000149315224045811 |
| 2024 Q2 | 51 | $438M | +0.2% | 13F-HR | 8/14/2024 | 000149315224032150 |
| 2024 Q1 | 52 | $459M | — | RESTATEMENT | 5/29/2024 | 000149315224021780 |
| 2024 Q1 | 51 | $437M | +16.2% | 13F-HR | 5/15/2024 | 000149315224019869 |
| 2023 Q4 | 47 | $376M | +22.5% | 13F-HR | 2/14/2024 | 000149315224006653 |
| 2023 Q3 | 41 | $307M | −26.6% | 13F-HR | 11/15/2023 | 000149315223041364 |
| 2023 Q2 | 47 | $418M | +25.1% | 13F-HR | 8/14/2023 | 000149315223028636 |
| 2023 Q1 | 41 | $334M | +16.0% | 13F-HR | 5/15/2023 | 000149315223016769 |
| 2022 Q4 | 40 | $288M | +19.0% | 13F-HR | 2/10/2023 | 000149315223004277 |
| 2022 Q3 | 42 | $242M | +9.0% | 13F-HR | 11/14/2022 | 000149315222032068 |
| 2022 Q2 | 47 | $222M | −31.1% | 13F-HR | 8/15/2022 | 000149315222022856 |
| 2022 Q1 | 45 | $322M | −31.6% | 13F-HR | 5/16/2022 | 000149315222013764 |
| 2021 Q4 | 39 | $471M | −12.0% | 13F-HR | 2/14/2022 | 000149315222004434 |
| 2021 Q3 | 48 | $535M | — | 13F-HR | 11/16/2021 | 000149315221028799 |
About
Opaleye Management Inc.
23 processed 13Fs on this site · 2021 Q3–2026 Q2